NCT00001941View on ClinicalTrials.gov

Anti-Tac for Treatment of Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
HTLV-I InfectionT Cell Leukemia
Interventions
BIOLOGICAL

daclizumab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001941 - Anti-Tac for Treatment of Leukemia | Biotech Hunter | Biotech Hunter